Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | ELANE | P08246 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8587545 | 0.88 | POLB (0.70) | POLBELANEKMT2AUSP2L3MBTL1 | |
| SCHEMBL8316646 | 0.83 | POLB (0.63) | POLBKMT2AUSP2L3MBTL1HTT | |
| SCHEMBL4608682 | 0.83 | POLB (1.00) | POLBELANEKMT2AUSP2L3MBTL1 | |
| SCHEMBL6748812 | 0.81 | POLB (0.70) | POLBELANEKMT2AUSP2L3MBTL1 | |
| SCHEMBL27908646 | 0.81 | POLB (0.70) | POLBELANEKMT2AUSP2L3MBTL1 | |
| SCHEMBL23487601 | 0.81 | POLB (0.65) | POLBELANEKMT2AUSP2L3MBTL1 | |
| SCHEMBL10949493 | 0.80 | POLB (0.76) | POLBELANEKMT2AUSP2L3MBTL1 | |
| SCHEMBL10782887 | 0.80 | POLB (0.76) | POLBELANEKMT2AUSP2L3MBTL1 | |
| SCHEMBL10958586 | 0.80 | POLB (0.76) | POLBELANEKMT2AUSP2L3MBTL1 | |
| SCHEMBL234456 | 0.80 | POLB (0.76) | POLBELANEKMT2AUSP2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468464-B2 | Resorcinol derivatives for skin | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1861353-B1 | NOVEL RESORCINOL DERIVATIVES FOR SKIN | UNILEVER PLC (GB) | 2008-10-08 | — | — | EP | disclosed |
| US-20080131382-A1 | Novel Resorcinol Derivatives for Skin | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| EP-1861353-A1 | NOVEL RESORCINOL DERIVATIVES FOR SKIN | UNILEVER PLC (GB) | 2007-12-05 | — | — | EP | disclosed |
| US-20060210498-A1 | Novel resorcinol derivatives for skin | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006097224-A1 | NOVEL RESORCINOL DERIVATIVES FOR SKIN | UNILEVER PLC (GB) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080131382-A1 | Novel Resorcinol Derivatives for Skin | NR1H2, CYP1B1, NR0B1 | POLB 920/4885ELANE 1493/4885KMT2A 2077/4885 |
| US-20060210498-A1 | Novel resorcinol derivatives for skin | NR1H2, CYP1B1, NR0B1 | POLB 920/4885ELANE 1493/4885KMT2A 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.